{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-003610","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2022-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.940521+00:00","generated_at":"2026-06-26T22:40:13.476226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Altimmune reports Q4 2021 net loss of $23.9M ($0.57/share); cash $190.3M; pemvidutide trials on track","bullets":["Net loss $23.9M ($0.57 per share) vs $10.6M ($0.29) in Q4 2020; R&D expense doubled to $20.2M on pemvidutide development.","Cash, equivalents and short-term investments of $190.3M at Dec 31, 2021; revenue $3.3M vs $2.3M.","Pemvidutide Phase 1b NAFLD trial >90% enrolled; topline data expected Q3 2022.","Phase 2 MOMENTUM obesity trial (48 wks) initiation expected Q1 2022; interim data at 24 wks in Q4 2022.","HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; readout expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-003610","json":"https://secwatch.observer/filing/0001558370-22-003610.json","markdown":"https://secwatch.observer/filing/0001558370-22-003610.md","text":"https://secwatch.observer/filing/0001558370-22-003610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000155837022003610/0001558370-22-003610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000155837022003610/alt-20220315x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:40:13.476226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}